Century Lithium Corp. (TSX-V:LCE, OTCQX:CYDVF), the owner of the Angel Island lithium project in Nevada, is poised to benefit from the inevitable upturn in lithium demand and pricing, analysts at Noble Capital Markets believe.
“Angel Island is one of a few advanced lithium projects being developed in the United States to provide an end-to-end process to produce battery-grade lithium,” analysts wrote.
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs.
Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our ageing dogs,” he said, adding that the study meets a significant unmet need.
The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the agency said last week.
The program will prioritize novel treatments and improved diagnostics for poultry, along with vaccine development.
Ethernity Networks Ltd (AIM:ENET, OTCQB:ENETF) told investors it has extended its existing aerospace contract with a Tier 1 US-based customer.
An original $1.05 million deal arrangement, first announced in June, was increased by $290,000 to $1.34 million, with the work due to be delivered over the next three months.
Ethernity said It expects further revenue from this customer during the second half of 2025.
Asiamet Resources Ltd (AIM:ARS, OTC:KMGLF) told investors it is close to completing the optimised Definitive Feasibility Study (DFS) for the BKM Copper Project in Central Kalimantan, Indonesia.
The company confirmed that all major engineering and technical work is complete, with only supplementary analysis on power supply outstanding.
Kairos Minerals Ltd managing director Dr Peter Turner discusses the company's Mt York Gold Project.
In this latest episode of After Market, Race Oncology Ltd CEO and Managing Director Daniel Tillett spoke with Proactive's Jonathan Jackson about updating an older, previously approved chemotherapy drug to reduce side effects, particularly cardiac-related risks, while maintaining or enhancing therapeutic efficacy.